CRNX vs ACVA vs KAR vs RCUS vs CPRT

For growth investors, Crinetics Pharmaceuticals, Inc.

(CRNX) is the stronger pick with 640. 7% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). OPENLANE, Inc. (KAR) offers the better valuation at 16. 7x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Crinetics Pharmaceuticals, Inc. (CRNX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OPENLANE, Inc.

(KAR) is the cheapest at 16. 7x versus Copart, Inc. at 21. 3x. On forward P/E, OPENLANE, Inc. is actually cheaper at 19. 3x.

Over the past 5 years, Crinetics Pharmaceuticals, Inc.

(CRNX) delivered a total return of +130. 9%, compared to -81. 0% for ACV Auctions Inc. (ACVA). Over 10 years, the gap is even starker: CPRT returned +528. 5% versus ACVA's -79. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Copart, Inc.

(CPRT) is the lower-risk stock at 0. 51β versus Arcus Biosciences, Inc. 's 1. 84β — meaning RCUS is approximately 263% more volatile than CPRT relative to the S&P 500. On balance sheet safety, Copart, Inc. (CPRT) carries a lower debt/equity ratio of 1% versus 93% for OPENLANE, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Crinetics Pharmaceuticals, Inc.

(CRNX) is pulling ahead at 640. 7% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: OPENLANE, Inc. grew EPS 264. 4% year-over-year, compared to -34. 1% for Crinetics Pharmaceuticals, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Copart, Inc.

(CPRT) is the more profitable company, earning 33. 4% net margin versus -60. 5% for Crinetics Pharmaceuticals, Inc. — meaning it keeps 33. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPRT leads at 36. 5% versus -67. 1% for CRNX. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OPENLANE, Inc.

(KAR) trades at 19. 3x forward P/E versus 31. 8x for ACV Auctions Inc. — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRNX: 131. 1% to $86. 60.

In this comparison, KAR (1.

3% yield) pays a dividend. CRNX, ACVA, RCUS, CPRT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Copart, Inc.

(CPRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +528. 5% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CPRT: +528. 5%, RCUS: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CRNX (Healthcare) and ACVA (Consumer Cyclical) and KAR (Consumer Cyclical) and RCUS (Healthcare) and CPRT (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CRNX is a small-cap high-growth stock; ACVA is a small-cap high-growth stock; KAR is a small-cap deep-value stock; RCUS is a small-cap quality compounder stock; CPRT is a mid-cap quality compounder stock. KAR pays a dividend while CRNX, ACVA, RCUS, CPRT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.